VA
PLRX icon

Verdad Advisers’s Pliant Therapeutics PLRX Stock Holding History

Verdad Advisers’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
281,343
+183,023
+186% +$223K 0.31% 112
2026
Q1 		$124K Buy
+98,320
New +$124K 0.14% 149

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Verdad Advisers's PLRX Position: Q2 2026 in Review

Verdad Advisers increased its Pliant Therapeutics (PLRX) stake by 186% in Q2 2026, buying an estimated $223K and bringing the position to 281,343 shares worth $321K. The position accounts for 0.31% of the portfolio, ranked #112.

Verdad Advisers first reported a position in PLRX in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Verdad Advisers held 281,343 shares of Pliant Therapeutics worth $321K as of Q2 2026.
  • Verdad Advisers bought 183,023 Pliant Therapeutics shares in Q2 2026, an estimated $223K.
  • Pliant Therapeutics made up 0.31% of Verdad Advisers's portfolio in Q2 2026, its #112 holding.
  • Verdad Advisers first reported a position in Pliant Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.